Cavidi secures ALMI grant to expand presence in US market

News   •   May 22, 2018 07:56 GMT

Cavidi has been granted matching funds to develop a US market strategy in the research area of viral vectors used to transfect genes in next-generation clinical applications such a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR). Applications include quantified potency assessment of viral vectors used in emerging vaccines and gene therapies to treat a wide range of diseases.

Cavidi finalists in Uppsala Innovation Award 2018

News   •   Apr 21, 2018 13:21 GMT

Cavidi were proud to be nominated as a finalist for the Innovation Award for the Uppsala region among all companies. http://foretagargalanuppsala.se/hem/finalister2018/

Innovation success is mission possible at Cavidi

News   •   Apr 20, 2018 09:33 GMT

Cavidi an HIV diagnostics industry leader sets sights on virus containment

News   •   Apr 13, 2018 11:07 GMT

The HIV virus has puzzled scientist around the world for decades. After having remained dormant since its discovery in the 1930's, fifty years later the virus caused one of the worst pandemics the world has seen in modern times. The World Trade Center in Malmö Sweden is home to Cavidi, a medical science company with a mission to contain the spread of this insidious virus known as HIV/AIDS.

EIB Venture Debt launch event March 22, 2018, Luxembourg

News   •   Apr 03, 2018 12:33 GMT

VP of European Investment Bank Ambroise FAYOLLE presents Innovation award to John Reisky de Dubnic, CEO Cavidi. Cavidi was the first to receive funding with debt placement of €10,000,000 loan from the EIB Venture Debt product.

Cavidi with new financial strength is getting ready to fill an important gap in the global fight against HIV

News   •   Feb 23, 2018 09:00 GMT

Cavidi closes US$ 11.5 million financing with Impilo

Press Releases   •   Feb 21, 2018 08:00 GMT

Cavidi announced today a US$ 11.5 million (SEK 90m) investment from Impilo, a leading investment firm focused on Nordic health care companies.

CAVIDI secures €7.8 million in new investment

Press Releases   •   Jul 26, 2017 14:52 GMT

New investors from the industrial sector bring strong segment experience to support the ongoing global scale up of Cavidi’s unique technology.

Cavidi at ASLM2016

News   •   Dec 02, 2016 10:56 GMT

Partners in Health begin VL testing at St Marc Clinic, Haiti

News   •   May 11, 2016 08:00 GMT

Partners in Health have begun to use Cavidi's ExaVir Load for Viral Load testing of HIV patients in Haiti

Contacts 1 contact

  • Press Contact
  • Corporate Communications
  • ufandrewsh.oldscwrfield@cavidi.snde
  • +46(0)702798454

About Cavidi

Biotech from Sweden making diagnostics more accessible to everyone

Advances in medical science are making more and more diseases treatable. And access to these treatments is increasing around the world. But to get the most from treatment researchers, doctors and patients also need access to accurate medical diagnostic tests. That’s our focus.

We began this work in 1984 when a team of leading virologists from Uppsala University in Sweden founded Cavidi. For over two decades we have been devoted to developing innovative solutions for the health and life science sector to give doctors in every part of the world the tools they need.

Our customers include hospitals, patient clinics, private laboratories, the pharmaceutical industry and research institutions worldwide.

Address

  • Cavidi
  • Virdings Allé 2
  • 754 50 Uppsala, Sweden